The global breast cancer diagnosis market is evaluated at US$4.713 billion for the year 2019 and is projected to grow at a CAGR of 5.11% to reach the market size of US$6.680 billion by the year 2026.
Breast cancer is defined as the malignant tumor formed in the tissues of the breast and has emerged as leading cancer among women across the globe. Several tests are carried out by the doctors to diagnose the site of initiation as well as to know if cancer has metastasized to the other body parts or not. The breast cancer market is expected to show robust growth during the given forecast period which may be attributed to the rising prevalence of breast cancer across the globe. Furthermore, various initiatives are being implemented by the governments of countries and various organizations worldwide to spread awareness and assist in the early diagnosis of breast cancer which is anticipated to propel the market growth during the forecast period. Technological advancements such as the introduction of hybrid imaging techniques are also expected to augment the market growth in the coming years.
The outbreak of the novel coronavirus disease had a negative impact on the global breast cancer diagnosis market. Due to the lockdowns and the fear among individuals regarding COVID-19, the diagnosis of breast cancer was delayed during the pandemic, especially in 2020, which led to a decline in the market growth of the global breast cancer diagnosis market. For instance, according to an article published by the Department of Radiology, Kaohsiung Veterans General Hospital, Taiwan, in July 2021, the number of total breast biopsies, mammography-guided, and ultrasound-guided biopsies decreased by 17%, 23%, and 14%, respectively, during the COVID-19 pandemic (between January and July 2020) compared to the same period in 2019 (pre-COVID-19).
Rising prevalence of breast cancer worldwide.
The cases of breast cancer have been increasing constantly all over the globe which has led to an increased need for its diagnosis and treatment. According to WHO, 2.3 million females were diagnosed with breast cancer in 2020 with the number of deaths accounting for 685 thousand. Furthermore, it has surpassed lung cancer in terms of the number of new cases per year and accounts for 11.7% of the total cancer cases worldwide. The World Cancer Research Fund International and the WHO states that the incidence of breast cancer has increased by 20% globally between 2008 and 2020 while the mortality has increased by 14%. The cases of breast cancer are projected to continue surging in the coming years as well which is anticipated to propel the growth of the global breast cancer diagnosis market during the forecast period. The American Cancer Society estimates that the number of diagnosed new cases of invasive breast cancer in the United States will be 281,550 in women and 2,650 cases will be diagnosed among men. Furthermore, as per the American Cancer Society, an estimated death of 44,000 people, including 43,600 women and 530 men, is projected to occur in the year 2021.
Government initiatives for increasing breast cancer diagnosis.
The governments of countries around the world have been concerned regarding the continuous spread of breast cancer which can have a negative impact on a country's economic condition as well. As a result, governments are launching new initiatives to tackle the rising of breast cancer by increasing awareness and proving aid for early diagnosis. The government of Australia runs the "BreastScreen Australia Program" which is a joint initiative of the Australian and state and territory governments. The program is aimed at diagnosing breast cancer at an early stage and consequently reducing illness and death from breast cancer. The Australian government has announced in May 2021 that their federal budget will include more than $100 million for breast and cervical cancer screening programs. In February 2021, the European Commission presented its "Europe's Beating Cancer Plan" which is aimed at improving cancer prevention, treatment, and care in the European Union. One of the four key action areas of the plan includes the target of ensuring that 90% of the EU population who qualify for breast cancer screenings, among few other cancer types, are offered screening by 2025. Various other initiatives are being launched by governments all over the globe which is anticipated to surge the diagnosis of breast cancer and hence is projected to propel the market growth in the coming years.
North America to hold a significant market share.
Geographically, the North American region is anticipated to hold a significant market share owing to a high incidence rate of breast cancer in the region. According to the WHO, North America has an age-standardized (world) incidence rate of 89.4 per 100,000, which is only behind “Australia & New Zealand” and “Western Europe”. Furthermore, a highly developed healthcare system and high awareness among the population are some other prominent factors behind the market dominance of North America. The Asia Pacific region is anticipated to witness substantial growth due to the rising incidences of breast cancer in the region, coupled with various initiatives implemented by the governments to spread awareness and for early detection of breast cancer.
|Market size value in 2019||US$4.713 billion|
|Market size value in 2026||US$6.680 billion|
|Growth Rate||CAGR of 5.11% from 2019 to 2026|
|Forecast Unit (Value)||USD Billion|
|Segments covered||Diagnostic Techniques, Cancer Type, End-User, And Geography|
|Regions covered||North America, South America, Europe, Middle East and Africa, Asia Pacific|
|Companies covered||Abbott, Hologic Inc., F. Hoffmann-La Roche Ltd, GE Healthcare, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Siemens AG, Fujifilm Holdings Corporation, Myriad Genetics, Carestream Health|
|Customization scope||Free report customization with purchase|
By Diagnostic Techniques
By Cancer Type
BRCA Breast Cancer
ER & PR Breast Cancer
HER 2 Breast Cancer
EGFR Mutation Test Breast Cancer
Hospitals and Clinics
Cancer Research Centers
Middle East and Africa
Frequently Asked Questions (FAQs)
Q1. What will be the breast cancer diagnosis market size by 2026?
A1. The breast cancer diagnosis market is projected to reach a market size of US$6.680 billion by 2026.
Q2. What is the size of global breast cancer diagnosis market?
A2. Breast Cancer Diagnosis Market was valued at US$4.713 billion in 2019.
Q3. What are the growth prospects for breast cancer diagnosis market?
A3. The global breast cancer diagnosis market is projected to grow at a CAGR of 5.11% during the forecast period.
Q4. What factors are anticipated to drive the breast cancer diagnosis market growth?
A4. The breast cancer market is expected to show robust growth during the given forecast period which may be attributed to the rising prevalence of breast cancer across the globe.
Q5. Which region holds the maximum market share of the breast cancer diagnosis market?
A5. Geographically, the North American region is anticipated to hold a significant share of the breast cancer diagnosis market owing to a high incidence rate of breast cancer in the region.
1.1. Market Definition
1.2. Market Segmentation
2. Research Methodology
2.1. Research Data
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of End-Users
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Global Breast Cancer Diagnosis Market Analysis, by Diagnostic Techniques
5.4. Laboratory Tests
6. Global Breast Cancer Diagnosis Market Analysis, by Cancer Type
6.2. BRCA Breast Cancer
6.3. ER & PR Breast Cancer
6.4. HER 2 Breast Cancer
6.5. EGFR Mutation Test Breast Cancer
7. Global Breast Cancer Diagnosis Market Analysis, by End-User
7.2. Hospitals and Clinics
7.3. Cancer Research Centers
7.4. Diagnostic Laboratories
8. Global Breast Cancer Diagnosis Market Analysis, by Geography
8.2. North America
8.3. South America
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.6. Asia Pacific
8.6.4. South Korea
8.6.9. New Zealand
9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. Company Profiles
10.2. Hologic Inc.
10.3. F. Hoffmann-La Roche Ltd
10.4. GE Healthcare
10.5. Thermo Fisher Scientific Inc.
10.6. Koninklijke Philips N.V.
10.7. Siemens AG
10.8. Fujifilm Holdings Corporation
10.9. Myriad Genetics
10.10. Carestream Health
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
Koninklijke Philips N.V.
Fujifilm Holdings Corporation
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.